EIGER BIOPHARMACEUTICALS, INC. Financials Eiger BioPharmaceuticals, Inc.
Equities
EIGR
US28249U2042
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.67 USD | -12.17% |
|
+11.72% | -60.36% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 365 | 399.8 | 176.3 | 52.01 | 9.964 | 3.954 | - | - |
| Enterprise Value (EV) 1 | 300.4 | 302.2 | 176.3 | 52.01 | 9.964 | 3.954 | 3.954 | 3.954 |
| P/E ratio | -4.84 x | -5.32 x | -5.19 x | -0.51 x | -0.13 x | -0.17 x | -0.74 x | -0.89 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 14.5 x | 3.86 x | 0.63 x | 0.16 x | 0.12 x | 0.12 x |
| EV / Revenue | - | - | 14.5 x | 3.86 x | 0.63 x | 0.16 x | 0.12 x | 0.12 x |
| EV / EBITDA | - | - | -2,300,123 x | -562,561 x | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 817 | 1,084 | 1,133 | 1,469 | 1,479 | 1,481 | - | - |
| Reference price 2 | 447.0 | 368.7 | 155.7 | 35.40 | 6.735 | 2.670 | 2.670 | 2.670 |
| Announcement Date | 3/13/20 | 3/9/21 | 3/10/22 | 3/17/23 | 4/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 12.14 | 13.48 | 15.77 | 25.22 | 32.65 | 34.36 |
| EBITDA | - | - | -76.66 | -92.45 | - | - | - | - |
| EBIT 1 | -68.9 | -62.15 | -76.94 | -92.74 | -71.79 | -21.54 | -6.221 | -5.041 |
| Operating Margin | - | - | -633.66% | -687.78% | -455.12% | -85.42% | -19.05% | -14.67% |
| Earnings before Tax (EBT) 1 | -70.25 | -65.05 | -33.85 | -96.75 | -74.96 | -24.84 | -9.594 | -8.339 |
| Net income 1 | -70.25 | -65.05 | -33.92 | -96.78 | -74.96 | -24.84 | -9.594 | -8.339 |
| Net margin | - | - | -279.34% | -717.71% | -475.26% | -98.49% | -29.38% | -24.27% |
| EPS 2 | -92.40 | -69.30 | -30.00 | -69.60 | -50.78 | -15.60 | -3.600 | -3.000 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/13/20 | 3/9/21 | 3/10/22 | 3/17/23 | 4/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.039 | 3.36 | 2.673 | 4.091 | 4.024 | 2.696 | 4.118 | 4.643 | 3.209 | 3.803 | 5.548 | 6.052 | 6.557 | 7.061 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -21.85 | -20.91 | -21.82 | -20.08 | -26.37 | -24.47 | -22.26 | -19.98 | -16.93 | -12.61 | -7.22 | -5.147 | -4.773 | -4.399 |
| Operating Margin | -719.02% | -622.44% | -816.31% | -490.83% | -655.29% | -907.68% | -540.63% | -430.35% | -527.52% | -331.69% | -130.14% | -85.05% | -72.79% | -62.3% |
| Earnings before Tax (EBT) 1 | -22.21 | -21.75 | -22.63 | -21.87 | -27.11 | -25.14 | -22.78 | -20.69 | -18.03 | -13.45 | -7.927 | -5.951 | -5.641 | -5.318 |
| Net income 1 | -22.22 | -21.77 | -22.64 | -21.88 | -27.11 | -25.14 | -22.78 | -20.7 | -18.03 | -13.45 | -7.927 | -5.951 | -5.641 | -5.318 |
| Net margin | -731.26% | -647.86% | -847.1% | -534.93% | -673.73% | -932.42% | -553.28% | -445.72% | -561.86% | -353.77% | -142.88% | -98.33% | -86.03% | -75.32% |
| EPS 2 | -19.50 | -19.20 | -19.20 | -15.30 | -18.60 | -16.80 | -15.60 | -14.10 | -12.30 | - | -5.400 | -3.900 | -3.600 | -2.700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/10/22 | 5/5/22 | 8/4/22 | 11/3/22 | 3/17/23 | 5/11/23 | 8/14/23 | 11/9/23 | 4/8/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 64.6 | 97.6 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -40.5% | -152% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.48 | 0.26 | 0.23 | - | - | - | - | - |
| Capex / Sales | - | - | 1.85% | - | - | - | - | - |
| Announcement Date | 3/13/20 | 3/9/21 | 3/10/22 | 3/17/23 | 4/8/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.67
USD
Average target price
30
USD
Spread / Average Target
+1,023.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.36% | 3.95M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- EIGR Stock
- Financials Eiger BioPharmaceuticals, Inc.
